miércoles, 22 de julio de 2026

I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer The FDA’s approval of Lipfendra is reflective of the attention economy driving interests within prevention

https://www.statnews.com/2026/07/22/lipfendra-enlicitide-merck-cholesterol-barriers/ By Vishal KhetpalJuly 22, 2026 Khetpal is a preventive cardiologist.

No hay comentarios: